Hims & Hers Launches FDA-Approved Weight Loss Medications
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Should l Buy HIMS?
Source: Newsfilter
- Increased Medication Access: Hims & Hers, in collaboration with Novo Nordisk, has launched a range of FDA-approved GLP-1 medications, including the only weight loss pill Wegovy®, enabling eligible customers to access these treatments at more affordable prices, which is expected to significantly enhance their health management capabilities.
- Weight Loss Potential: Eligible customers can lose up to 20% of their body weight using Wegovy® under clinical guidance, which, combined with diet and exercise, is anticipated to improve overall health outcomes and strengthen brand loyalty among users.
- New Membership Program: Hims & Hers has introduced a new weight loss membership plan that includes comprehensive support services such as 24/7 direct access to providers and personalized nutrition guidance, with an initial fee of $39 for the first month and $149 thereafter, aimed at increasing customer success rates through ongoing support.
- Market Leadership: This expansion positions Hims & Hers as the largest global consumer health platform offering affordable access to FDA-approved medications, further solidifying its leadership in the health management sector and driving future business growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 24.290
Low
16.50
Averages
32.95
High
60.00
Current: 24.290
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Health Stock Rises on Peptide Policy Changes
- Policy Impact: Health Secretary Kennedy announced that the FDA will remove 12 peptides from the high-risk category, potentially allowing Hims & Hers Health (HIMS) to expand in the peptide market, leading to a 14% stock price increase.
- Expert Evaluation Meetings: Starting in July, the Pharmacy Compounding Advisory Committee will rigorously assess each peptide's scientific merits and safety, which may shift market demand away from black market products and enhance regulatory access.
- Positive Market Reaction: Retail sentiment around HIMS shifted from 'bearish' to 'bullish', with message volume increasing significantly, indicating strong market interest in peptides and investor hopes for stock prices to rise to $45 or even $100.
- Analyst Rating Discrepancies: Among the 15 analysts covering HIMS, only 3 rated it as 'Buy', while 12 maintained a 'Hold' rating, with a 12-month average price target of $24, reflecting a cautious outlook on the stock's future performance.
See More
Hims & Hers Health Eyes Peptides as Growth Potential Post-GLP-1
- Peptide Market Potential: Hims & Hers Health is focusing on peptides as a new growth opportunity to replace GLP-1 driven growth, with rising market demand despite limited clinical evidence, potentially opening new revenue streams for the company.
- FDA Review Process: The FDA plans to hold a Pharmacy Compounding Advisory Committee meeting in July 2026 to review the potential inclusion of peptides, providing Hims with a clearer regulatory path, although immediate revenue impact is not expected.
- Acquisition and Innovation: Hims made a significant move by acquiring a California-based peptide facility in February 2025, with CEO Andrew Dudum describing peptide demand as “future-facing innovation,” as the company actively explores expanding access to peptide therapies in alignment with FDA guidance.
- Positive Market Reaction: Following HHS Secretary Robert F. Kennedy's announcement of the FDA's review of peptides, Hims' shares rose to around $26, indicating investor interest in the peptide market potential, although it will take time to validate profitability.
See More
Health Care Stocks Decline as NYSE Index Falls 0.8%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly declined, with the NYSE Health Care Index falling by 0.8%, indicating a weakening market confidence in the sector that could impact short-term investor decisions.
- Diminished Market Sentiment: This drop may be linked to uncertainties in the overall economic environment, leading investors to question the future growth potential of the health care sector, resulting in capital outflows from this segment.
- Investor Reactions: As health care stocks decline, investors may reassess their portfolios, considering reallocating funds to other better-performing sectors to mitigate risk and seek higher returns.
- Uncertain Industry Outlook: The future performance of the health care sector may be influenced by policy changes and fluctuations in market demand, prompting investors to closely monitor relevant developments to adjust their investment strategies accordingly.
See More
Hims & Hers Explores New Opportunities in Peptides
- FDA Meeting Impact: HHS Secretary Robert F. Kennedy announced that the FDA will convene a Pharmacy Compounding Advisory Committee to review peptides for potential inclusion on the 503A bulk list, leading to a share price increase for Hims on Thursday, reflecting market optimism about its future potential.
- Revenue Growth Potential: Hims & Hers is actively expanding its peptide business, with CEO Andrew Dudum stating that peptide demand represents 'future-facing innovation,' which could open new revenue streams for the company, although it will not immediately translate into revenue.
- Clearer Regulatory Path: Leerink Partners views the FDA's review of peptides as a positive development that could provide Hims with a clearer regulatory path to scale peptide therapies, although analysts note that clinical evidence remains limited and will not significantly impact financial performance in the short term.
- Market Opportunity Exploration: Hims' Chief Medical Officer Patrick Carroll emphasized that peptide therapies could help improve Americans' health, with the company's goal of bringing peptide treatments into a regulated medical environment, showcasing its strategic foresight in the health tech sector.
See More
Hims & Hers Shares Surge on FDA's Regulatory Shift for Peptides
- Stock Surge: Hims & Hers (HIMS) shares rose as much as 11% in premarket trading on Thursday, poised to extend their approximately 14% rally from Wednesday, indicating strong market optimism regarding the company's future prospects.
- FDA Regulatory Impact: HHS Secretary Robert F. Kennedy Jr. announced that the FDA is seeking to lift restrictions on 12 peptides, a move that could shift market demand away from black market sources and enhance legitimate access to these products.
- Production Licensing Outlook: The FDA plans to convene an advisory committee of independent experts in July to review evidence on certain peptides, and if regulations are eased, Hims & Hers has indicated plans to offer these products, potentially expanding its market share.
- Strategic Company Adjustments: Hims Chief Medical Officer Pat Carroll stated that the FDA's actions will help transition peptide therapies from the gray market to trusted channels, reflecting the company's commitment to consumer safety and clinical excellence.
See More
S&P 500 Index Surpasses 7,000 Mark
- Market Sentiment Rebound: The S&P 500 index surpassed 7,000 on Wednesday, driven by easing Middle East tensions and strong tech performance, with retail investor sentiment shifting from neutral to bullish, indicating a recovery in market confidence.
- Tech Stock Momentum: The Nasdaq index also crossed 26,000 in the previous session, with Nasdaq futures up 0.4% and S&P 500 futures gaining 0.2%, reflecting sustained investor interest and optimism in technology stocks.
- TSMC's Strong Earnings: Taiwan Semiconductor Manufacturing Company reported a record Q1 profit jump of 58%, exceeding estimates, and expects Q2 revenue between $39 billion and $40.2 billion with gross margins of 65.5% to 67.5%, highlighting robust market demand and profitability.
- Economic Data Watch: Investors are closely monitoring upcoming economic data releases, including Initial Jobless Claims and the Philadelphia Fed Manufacturing Index, which could influence market momentum and determine future investment strategies.
See More
Hims & Hers Health Stock Rises on Peptide Policy Changes
- Policy Impact: Health Secretary Kennedy announced that the FDA will remove 12 peptides from the high-risk category, potentially allowing Hims & Hers Health (HIMS) to expand in the peptide market, leading to a 14% stock price increase.
- Expert Evaluation Meetings: Starting in July, the Pharmacy Compounding Advisory Committee will rigorously assess each peptide's scientific merits and safety, which may shift market demand away from black market products and enhance regulatory access.
- Positive Market Reaction: Retail sentiment around HIMS shifted from 'bearish' to 'bullish', with message volume increasing significantly, indicating strong market interest in peptides and investor hopes for stock prices to rise to $45 or even $100.
- Analyst Rating Discrepancies: Among the 15 analysts covering HIMS, only 3 rated it as 'Buy', while 12 maintained a 'Hold' rating, with a 12-month average price target of $24, reflecting a cautious outlook on the stock's future performance.
See More
Hims & Hers Health Eyes Peptides as Growth Potential Post-GLP-1
- Peptide Market Potential: Hims & Hers Health is focusing on peptides as a new growth opportunity to replace GLP-1 driven growth, with rising market demand despite limited clinical evidence, potentially opening new revenue streams for the company.
- FDA Review Process: The FDA plans to hold a Pharmacy Compounding Advisory Committee meeting in July 2026 to review the potential inclusion of peptides, providing Hims with a clearer regulatory path, although immediate revenue impact is not expected.
- Acquisition and Innovation: Hims made a significant move by acquiring a California-based peptide facility in February 2025, with CEO Andrew Dudum describing peptide demand as “future-facing innovation,” as the company actively explores expanding access to peptide therapies in alignment with FDA guidance.
- Positive Market Reaction: Following HHS Secretary Robert F. Kennedy's announcement of the FDA's review of peptides, Hims' shares rose to around $26, indicating investor interest in the peptide market potential, although it will take time to validate profitability.
See More
Health Care Stocks Decline as NYSE Index Falls 0.8%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly declined, with the NYSE Health Care Index falling by 0.8%, indicating a weakening market confidence in the sector that could impact short-term investor decisions.
- Diminished Market Sentiment: This drop may be linked to uncertainties in the overall economic environment, leading investors to question the future growth potential of the health care sector, resulting in capital outflows from this segment.
- Investor Reactions: As health care stocks decline, investors may reassess their portfolios, considering reallocating funds to other better-performing sectors to mitigate risk and seek higher returns.
- Uncertain Industry Outlook: The future performance of the health care sector may be influenced by policy changes and fluctuations in market demand, prompting investors to closely monitor relevant developments to adjust their investment strategies accordingly.
See More
Hims & Hers Explores New Opportunities in Peptides
- FDA Meeting Impact: HHS Secretary Robert F. Kennedy announced that the FDA will convene a Pharmacy Compounding Advisory Committee to review peptides for potential inclusion on the 503A bulk list, leading to a share price increase for Hims on Thursday, reflecting market optimism about its future potential.
- Revenue Growth Potential: Hims & Hers is actively expanding its peptide business, with CEO Andrew Dudum stating that peptide demand represents 'future-facing innovation,' which could open new revenue streams for the company, although it will not immediately translate into revenue.
- Clearer Regulatory Path: Leerink Partners views the FDA's review of peptides as a positive development that could provide Hims with a clearer regulatory path to scale peptide therapies, although analysts note that clinical evidence remains limited and will not significantly impact financial performance in the short term.
- Market Opportunity Exploration: Hims' Chief Medical Officer Patrick Carroll emphasized that peptide therapies could help improve Americans' health, with the company's goal of bringing peptide treatments into a regulated medical environment, showcasing its strategic foresight in the health tech sector.
See More
Hims & Hers Shares Surge on FDA's Regulatory Shift for Peptides
- Stock Surge: Hims & Hers (HIMS) shares rose as much as 11% in premarket trading on Thursday, poised to extend their approximately 14% rally from Wednesday, indicating strong market optimism regarding the company's future prospects.
- FDA Regulatory Impact: HHS Secretary Robert F. Kennedy Jr. announced that the FDA is seeking to lift restrictions on 12 peptides, a move that could shift market demand away from black market sources and enhance legitimate access to these products.
- Production Licensing Outlook: The FDA plans to convene an advisory committee of independent experts in July to review evidence on certain peptides, and if regulations are eased, Hims & Hers has indicated plans to offer these products, potentially expanding its market share.
- Strategic Company Adjustments: Hims Chief Medical Officer Pat Carroll stated that the FDA's actions will help transition peptide therapies from the gray market to trusted channels, reflecting the company's commitment to consumer safety and clinical excellence.
See More
S&P 500 Index Surpasses 7,000 Mark
- Market Sentiment Rebound: The S&P 500 index surpassed 7,000 on Wednesday, driven by easing Middle East tensions and strong tech performance, with retail investor sentiment shifting from neutral to bullish, indicating a recovery in market confidence.
- Tech Stock Momentum: The Nasdaq index also crossed 26,000 in the previous session, with Nasdaq futures up 0.4% and S&P 500 futures gaining 0.2%, reflecting sustained investor interest and optimism in technology stocks.
- TSMC's Strong Earnings: Taiwan Semiconductor Manufacturing Company reported a record Q1 profit jump of 58%, exceeding estimates, and expects Q2 revenue between $39 billion and $40.2 billion with gross margins of 65.5% to 67.5%, highlighting robust market demand and profitability.
- Economic Data Watch: Investors are closely monitoring upcoming economic data releases, including Initial Jobless Claims and the Philadelphia Fed Manufacturing Index, which could influence market momentum and determine future investment strategies.
See More
